Lung cancer is the leading cancer killer of both men and women in the United States, leading to more than 150,000 deaths per year.
Maine's lung cancer rates are 30% higher than the national average.
Maine men have a 30% higher lung cancer rate than Maine women.
75% of lung cancer cases in Maine are detected late and are often not treatable.
Lung cancer screening leads to better all-cause mortality rate.
Low-dose computed tomography (LDCT) is a promising new screening tool for the early detection of lung cancer in high-risk individuals. Annual LDCT screening is recommended by the US Preventive Services Task Force (USPSTF) and is covered by the Centers for Medicare and Medicaid Services (CMS) and many health insurance companies for qualified patients.
Before the initial screening can occur, Centers for Medicare and Medicaid Services (CMS) requires that eligible patients participate in a lung cancer screening counseling and shared decision making visit by a physician or qualified non-physician practitioner. In shared decision making, patients and providers collaborate to make health decisions based on the best available evidence and the patient's values and preferences.Learn More
A four-year grant from the Bristol-Myers Squibb Foundation, Maine Cancer Foundation, and the Maine Economic Improvement Fund created this multidisciplinary, cross organizational effort that will span the state of Maine.
Additional funds are needed to achieve the full potential of this project. We need your support! Join us by making a tax-deductible gift today.donate now
JackWennberg, MD, MPH, Founder & Director Emeritus, The Dartmouth Institute for Health Policy & Clinical Practice